These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 34605873)

  • 1. Computational and in vitro experimental analyses of the Anti-COVID-19 potential of Mortaparib and MortaparibPlus.
    Kumar V; Sari AN; Meidinna HN; Dhanjal JK; Subramani C; Basu B; Kaul SC; Vrati S; Sundar D; Wadhwa R
    Biosci Rep; 2021 Oct; ():. PubMed ID: 34605873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational and in vitro experimental analyses of the anti-COVID-19 potential of Mortaparib and MortaparibPlus.
    Kumar V; Sari AN; Meidinna HN; Dhanjal JK; Subramani C; Basu B; Kaul SC; Vrati S; Sundar D; Wadhwa R
    Biosci Rep; 2021 Oct; 41(10):. PubMed ID: 34647577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mixtures of Three Mortaparibs with Enhanced Anticancer, Anti-Migration, and Antistress Activities: Molecular Characterization in p53-Null Cancer Cells.
    Wadhwa R; Yang S; Meidinna HN; Sari AN; Bhargava P; Kaul SC
    Cancers (Basel); 2024 Jun; 16(12):. PubMed ID: 38927944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutant p53
    Elwakeel A; Sari AN; Dhanjal JK; Meidinna HN; Sundar D; Kaul SC; Wadhwa R
    Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34207240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mortaparib, a novel dual inhibitor of mortalin and PARP1, is a potential drug candidate for ovarian and cervical cancers.
    Putri JF; Bhargava P; Dhanjal JK; Yaguchi T; Sundar D; Kaul SC; Wadhwa R
    J Exp Clin Cancer Res; 2019 Dec; 38(1):499. PubMed ID: 31856867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a new member of Mortaparib class of inhibitors that target mortalin and PARP1.
    Meidinna HN; Shefrin S; Sari AN; Zhang H; Dhanjal JK; Kaul SC; Sundar D; Wadhwa R
    Front Cell Dev Biol; 2022; 10():918970. PubMed ID: 36172283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and Characterization of Mortaparib
    Sari AN; Elwakeel A; Dhanjal JK; Kumar V; Sundar D; Kaul SC; Wadhwa R
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33671256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity.
    Essalmani R; Jain J; Susan-Resiga D; Andréo U; Evagelidis A; Derbali RM; Huynh DN; Dallaire F; Laporte M; Delpal A; Sutto-Ortiz P; Coutard B; Mapa C; Wilcoxen K; Decroly E; Nq Pham T; Cohen ÉA; Seidah NG
    J Virol; 2022 Apr; 96(8):e0012822. PubMed ID: 35343766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic potential of green tea catechin, (-)-epigallocatechin-3-
    Dinda B; Dinda S; Dinda M
    Phytomed Plus; 2023 Feb; 3(1):100402. PubMed ID: 36597465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contributions of human ACE2 and TMPRSS2 in determining host-pathogen interaction of COVID-19.
    Senapati S; Banerjee P; Bhagavatula S; Kushwaha PP; Kumar S
    J Genet; 2021; 100(1):. PubMed ID: 33707363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reactive Centre Loop Mutagenesis of SerpinB3 to Target TMPRSS2 and Furin: Inhibition of SARS-CoV-2 Cell Entry and Replication.
    Singh S; O'Reilly S; Gewaid H; Bowie AG; Gautier V; Worrall DM
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
    Li K; Meyerholz DK; Bartlett JA; McCray PB
    mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of SARS-CoV-2 cell entry: insight from
    Gyebi GA; Adegunloye AP; Ibrahim IM; Ogunyemi OM; Afolabi SO; Ogunro OB
    J Biomol Struct Dyn; 2022 Mar; 40(5):2121-2145. PubMed ID: 33089728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2 Entry Inhibitors Targeting Virus-ACE2 or Virus-TMPRSS2 Interactions.
    Lin H; Cherukupalli S; Feng D; Gao S; Kang D; Zhan P; Liu X
    Curr Med Chem; 2022; 29(4):682-699. PubMed ID: 33881969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Target-Centered Drug Repurposing Predictions of Human Angiotensin-Converting Enzyme 2 (ACE2) and Transmembrane Protease Serine Subtype 2 (TMPRSS2) Interacting Approved Drugs for Coronavirus Disease 2019 (COVID-19) Treatment through a Drug-Target Interaction Deep Learning Model.
    Choi Y; Shin B; Kang K; Park S; Beck BR
    Viruses; 2020 Nov; 12(11):. PubMed ID: 33218024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suite of TMPRSS2 Assays for Screening Drug Repurposing Candidates as Potential Treatments of COVID-19.
    Shrimp JH; Janiszewski J; Chen CZ; Xu M; Wilson KM; Kales SC; Sanderson PE; Shinn P; Schneider R; Itkin Z; Guo H; Shen M; Klumpp-Thomas C; Michael SG; Zheng W; Simeonov A; Hall MD
    ACS Infect Dis; 2022 Jun; 8(6):1191-1203. PubMed ID: 35648838
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Lawal B; Tsai SK; Wu ATH; Huang HS
    Arab J Chem; 2023 May; 16(5):104654. PubMed ID: 36777994
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Sun TK; Huang WC; Sun YW; Deng JS; Chien LH; Chou YN; Jiang WP; Lin JG; Huang GJ
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coronavirus Infection-Associated Cell Death Signaling and Potential Therapeutic Targets.
    Yapasert R; Khaw-On P; Banjerdpongchai R
    Molecules; 2021 Dec; 26(24):. PubMed ID: 34946543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat.
    Sun G; Sui Y; Zhou Y; Ya J; Yuan C; Jiang L; Huang M
    J Virol; 2021 Sep; 95(19):e0086121. PubMed ID: 34160253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.